S. S.
- Country
- Germany
- Department
- Hematology
Research Overview
- HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
- HOVON 156 AML: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.
Data & Insights
Has run more than one trial at 104 of 168 partner sites.
Specializations
Hematologic Malignancies
The investigator focuses on aggressive blood cancers, including Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, and high‑risk lymphomas such as Diffuse Large B‑Cell Lymphoma and Follicular Lymphoma.
- Targeted therapies for AML with adverse genetics
- Combination regimens for Ph‑positive ALL
- Novel agents in relapsed/refractory DLBCL
- Maintenance strategies for CLL with high‑risk cytogenetics
- Immunomodulatory approaches in MDS‑EB2
Research integrates molecular profiling to personalize treatment pathways across these hematologic entities.
Breast Cancer Therapeutics
Work in breast oncology spans ER‑positive/HER2‑negative Breast Cancer, HER2‑positive Breast Cancer, and Triple‑Negative Breast Cancer, addressing both early‑stage disease and advanced metastatic settings.
- Selective estrogen receptor degraders in endocrine‑resistant tumors
- Antibody‑drug conjugates for HER2‑positive early disease
- Immunotherapy combinations for triple‑negative disease
- Adjuvant CDK4/6 inhibition after standard endocrine therapy
- Biomarker‑driven neoadjuvant strategies
Efforts aim to improve invasive disease‑free survival and reduce recurrence across molecular subtypes.
Thoracic Oncology
The investigator’s thoracic portfolio includes Non‑Small Cell Lung Cancer and Small‑Cell Lung Cancer, with particular attention to metastatic disease and mutational sub‑groups.
- Checkpoint inhibitor plus chemotherapy regimens
- Targeted therapy for KRAS G12C‑mutant NSCLC
- Combination of anti‑angiogenic agents with immunotherapy
- First‑line treatment optimization for extensive‑stage SCLC
- Biomarker‑guided patient selection for novel agents
Clinical focus emphasizes extending progression‑free survival and overall survival in advanced thoracic cancers.
Dermatologic and Immune‑Mediated Diseases
In the field of skin and immune disorders, the investigator evaluates therapies for Atopic Dermatitis, Hidradenitis Suppurativa, Prurigo Nodularis, Chronic Spontaneous Urticaria, and Cutaneous Lupus Erythematosus.
- IL‑13 inhibition for severe atopic dermatitis
- Biologic agents targeting inflammatory pathways in HS
- Novel anti‑pruritic compounds for prurigo nodularis
- JAK inhibition in chronic urticaria
- Targeted immunotherapy for cutaneous lupus
Studies prioritize symptom relief, skin clearance, and quality‑of‑life outcomes.
Cardiovascular, Metabolic and Infectious Conditions
The investigator also contributes to research on acute cardiac events and metabolic disorders, including Acute Myocardial Infarction, Hypercholesterolemia, and emerging infectious challenges such as COVID‑19 and Invasive Candidiasis, alongside inflammatory bowel disease exemplified by Ulcerative Colitis.
- Self‑administered agents for early AMI symptom management
- RNA‑based therapies to achieve LDL‑C targets
- Antiviral and immunomodulatory strategies in COVID‑19
- Oral antifungal regimens for candidemia
- Biologic treatments for moderate‑to‑severe ulcerative colitis
These projects address acute care, chronic disease control, and infection‑related morbidity.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.